Zynex (NASDAQ:ZYXI) Issues FY 2024 Earnings Guidance

Zynex (NASDAQ:ZYXI) updated its FY 2024 earnings guidance on Tuesday. The company provided EPS guidance of 0.500- for the period, compared to the consensus EPS estimate of 0.480. The company issued revenue guidance of $227.0 million-, compared to the consensus revenue estimate of $227.4 million. Zynex also updated its FY24 guidance to $0.50 EPS.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on ZYXI. HC Wainwright increased their target price on Zynex from $20.00 to $21.00 and gave the stock a buy rating in a report on Friday, March 1st. Royal Bank of Canada increased their target price on Zynex from $13.00 to $15.00 and gave the stock an outperform rating in a report on Friday, March 1st.

Zynex Price Performance

Shares of ZYXI traded down $0.48 during trading hours on Tuesday, hitting $10.97. 156,977 shares of the company were exchanged, compared to its average volume of 233,517. The company has a market cap of $352.90 million, a price-to-earnings ratio of 40.63 and a beta of 0.48. Zynex has a fifty-two week low of $6.88 and a fifty-two week high of $14.75. The company has a quick ratio of 4.03, a current ratio of 4.74 and a debt-to-equity ratio of 1.26. The firm’s fifty day moving average is $12.35 and its 200 day moving average is $10.83.

Zynex (NASDAQ:ZYXI) last released its quarterly earnings data on Thursday, February 29th. The company reported $0.04 earnings per share for the quarter, missing the consensus estimate of $0.17 by ($0.13). The business had revenue of $47.28 million during the quarter, compared to analyst estimates of $54.53 million. Zynex had a net margin of 5.28% and a return on equity of 16.82%. The business’s quarterly revenue was down 3.1% compared to the same quarter last year. During the same period last year, the business earned $0.20 earnings per share. On average, equities analysts anticipate that Zynex will post 0.49 earnings per share for the current fiscal year.

About Zynex

Zynex, Inc, together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device.